Boxer Capital Management LLC Makes New $2.35 Million Investment in Bicara Therapeutics Inc. (NASDAQ:BCAX)

Boxer Capital Management LLC purchased a new stake in shares of Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 135,000 shares of the company's stock, valued at approximately $2,352,000. Boxer Capital Management LLC owned approximately 0.25% of Bicara Therapeutics at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the company. Jane Street Group LLC purchased a new stake in Bicara Therapeutics during the 3rd quarter valued at approximately $309,000. Barclays PLC bought a new position in shares of Bicara Therapeutics during the third quarter worth $255,000. Geode Capital Management LLC purchased a new position in Bicara Therapeutics during the third quarter valued at $1,239,000. SG Americas Securities LLC bought a new stake in Bicara Therapeutics in the 4th quarter valued at $147,000. Finally, Spire Wealth Management purchased a new stake in Bicara Therapeutics in the 4th quarter worth $31,000.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the company. Stifel Nicolaus set a $48.00 target price on Bicara Therapeutics in a report on Thursday, March 27th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $13.01 price objective on shares of Bicara Therapeutics in a research note on Thursday, March 13th. HC Wainwright lowered their target price on Bicara Therapeutics from $45.00 to $44.00 and set a "buy" rating for the company in a research report on Monday, April 7th. Wells Fargo & Company began coverage on shares of Bicara Therapeutics in a report on Thursday, April 17th. They issued an "underweight" rating and a $8.00 target price for the company. Finally, Wedbush reiterated an "outperform" rating and set a $31.00 price objective on shares of Bicara Therapeutics in a research report on Thursday, March 27th. One research analyst has rated the stock with a sell rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $32.43.

Bicara Therapeutics Stock Performance

NASDAQ:BCAX traded down $0.55 during mid-day trading on Wednesday, hitting $12.12. 132,838 shares of the stock traded hands, compared to its average volume of 481,967. Bicara Therapeutics Inc. has a 52 week low of $8.91 and a 52 week high of $28.09. The firm's 50 day moving average is $12.98 and its two-hundred day moving average is $15.77.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last released its earnings results on Thursday, March 27th. The company reported ($0.39) EPS for the quarter, missing analysts' consensus estimates of ($0.31) by ($0.08). Research analysts predict that Bicara Therapeutics Inc. will post -2.59 EPS for the current year.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.